Novel mechanisms for the antifibrotic action of nintedanib

American Journal of Respiratory Cell and Molecular Biology

Volumn 54, Issue 1, 2016, Pages 51-59

  Rangarajan, Sunad ^a   Kurundkar, Ashish ^a   Kurundkar, Deepali ^a   Bernard, Karen ^a   Sanders, Yan Y ^a   Ding, Qiang ^a   Antony, Veena B ^a   Zhang, Jianhua ^b   Zmijewski, Jaroslaw ^a   Thannickal, Victor J ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Autophagy; Fibroblasts; Fibrosis; Nintedanib; Transforming growth factor

Indexed keywords

BECLIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NINTEDANIB; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; APOPTOSIS REGULATORY PROTEIN; ATG7 PROTEIN, HUMAN; AUTOPHAGY RELATED PROTEIN 7; BECN1 PROTEIN, HUMAN; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; FIBRONECTIN; INDOLE DERIVATIVE; MEMBRANE PROTEIN; PROTEIN SERINE THREONINE KINASE; SMAD3 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; UBIQUITIN PROTEIN LIGASE;

ANTIFIBROTIC ACTIVITY; ARTICLE; AUTOPHAGY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACTIVITY; EFFECTOR CELL; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MICROSCOPY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME FACTOR;

APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY-RELATED PROTEIN 7; BECLIN-1; CELLS, CULTURED; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRONECTINS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; LUNG; MEMBRANE PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN-ACTIVATING ENZYMES;

EID: 84963807764     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0445OC     Document Type: Article

References (39)

1. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-1087.
2. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-2082.
3. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007;29:976-985.
4. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-4782.
5. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and antiinflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014;349:209-220.
6. Thannickal VJ, Toews GB, White ES, Lynch JP III, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004;55:395-417.
7. Rangarajan S, Dodson M, Zhang J, Thannickal V. Enhanced autophagy as a potential mechanism for the anti-fibrotic effects of BIBF-1120 in IPF [abstract]. Am J Respir Crit Care Med 2013;187:A5162.
8. Rangarajan S, Kurundkar A, Zhang J, Thannickal V. Non-canonical autophagy and the anti-fibrotic effects of BIBF-1120 in IPF [abstract]. Am J Respir Crit Care Med 2014;189:A5395.
9. Desai LP, Zhou Y, Estrada AV, Ding Q, Cheng G, Collawn JF, Thannickal VJ. Negative regulation of NADPH oxidase 4 by hydrogen peroxide-inducible clone 5 (Hic-5) protein. J Biol Chem 2014;289:18270-18278.
10. Zhou Y, Huang X, Hecker L, Kurundkar D, Kurundkar A, Liu H, Jin TH, Desai L, Bernard K, Thannickal VJ. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 2013;123:1096-1108.
11. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med 2013;368:651-662.
12. Patel AS, Lin L, Geyer A, Haspel JA, An CH, Cao J, Rosas IO, Morse D. Autophagy in idiopathic pulmonary fibrosis. PLoS One 2012;7:e41394.
13. Araya J, Kojima J, Takasaka N, Ito S, Fujii S, Hara H, Yanagisawa H, Kobayashi K, Tsurushige C, Kawaishi M, et al. Insufficient autophagy in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2013;304:L56-L69.
14. Ricci A, Cherubini E, Scozzi D, Pietrangeli V, Tabbi L, Raffa S, Leone L, Visco V, Torrisi MR, Bruno P, et al. Decreased expression of autophagic beclin 1 protein in idiopathic pulmonary fibrosis fibroblasts. J Cell Physiol 2013;228:1516-1524.
15. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007;3:542-545.
16. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012;8:445-544.
17. Codogno P, Mehrpour M, Proikas-Cezanne T. Canonical and noncanonical autophagy: variations on a common theme of self-eating? Nat Rev Mol Cell Biol 2012;13:7-12.
18. Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, Izumi K, Sone S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005;171:1279-1285.
19. Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J Pharmacol Exp Ther 2007;321:35-44.
20. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, Imatinib IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181:604-610.
21. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
22. Ahluwalia N, Shea BS, Tager AM. New therapeutic targets in idiopathic pulmonary fibrosis: aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med 2014;190:867-878.
23. Khalil N, O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH, Greenberg AH. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991;5:155-162.
24. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991;88:6642-6646.
25. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1:169-178.
26. Chen X, Wang H, Liao HJ, Hu W, Gewin L, Mernaugh G, Zhang S, Zhang ZY, Vega-Montoto L, Vanacore RM, et al. Integrin-mediated type II TGF-beta receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling. J Clin Invest 2014;124:3295-3310.
27. Allison SJ. Fibrosis: regulation of fibrotic signalling by TGF-beta receptor tyrosine phosphorylation. Nat Rev Nephrol 2014;10:484.
28. Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 2007;67:3752-3758.
29. Hu M, Che P, Han X, Cai GQ, Liu G, Antony V, Luckhardt T, Siegal GP, Zhou Y, Liu RM, et al. Therapeutic targeting of Src kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther 2014;351:87-95.
30. Michaelson JE, Ritzenthaler JD, Roman J. Regulation of serum-induced fibronectin expression by protein kinases, cytoskeletal integrity, and CREB. Am J Physiol Lung Cell Mol Physiol 2002;282:L291-L301.
31. Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-betadependent responses in human mesangial cells. FASEB J 2003;17:1576-1578.
32. Hecker L, Jagirdar R, Jin T, Thannickal VJ. Reversible differentiation of myofibroblasts by MyoD. Exp Cell Res 2011;317:1914-1921.
33. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. Cell 2011;146:682-695.
34. Juenemann K, Reits EA. Alternative macroautophagic pathways. Int J Cell Biol 2012;2012:189794.
35. Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, Ge W, Feng L, Lin X, Wang X, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 2011;6:e18691.
36. Rikiishi H. Autophagic action of new targeting agents in head and neck oncology. Cancer Biol Ther 2012;13:978-991.
37. Calabretta B, Salomoni P. Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors. Leuk Lymphoma 2011;52:54-59.
38. Sui X, Kong N, Zhu M, Wang X, Lou F, Han W, Pan H. Cotargeting EGFR and autophagy signaling: a novel therapeutic strategy for non-small-cell lung cancer. Mol Clin Oncol 2014;2:8-12.
39. Yu J, Parkhitko A, Henske EP. Autophagy: an 'Achilles' heel of tumorigenesis in TSC and LAM. Autophagy 2011;7:1400-1401.